Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Operating Leases (2019 - 2025)

ENDRA Life Sciences has reported Operating Leases over the past 3 years, most recently at $650477.0 for Q4 2021.

  • Quarterly Operating Leases rose 86.71% to $650477.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $650477.0 through Dec 2021, up 86.71% year-over-year, with the annual reading at $650477.0 for FY2021, 86.71% up from the prior year.
  • Operating Leases was $650477.0 for Q4 2021 at ENDRA Life Sciences, down from $680526.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $709385.0 in Q2 2021 and troughed at $331520.0 in Q1 2021.
  • The 3-year median for Operating Leases is $394412.0 (2020), against an average of $471860.1.
  • The largest YoY upside for Operating Leases was 86.9% in 2021 against a maximum downside of 15.95% in 2021.
  • A 3-year view of Operating Leases shows it stood at $409005.0 in 2019, then fell by 14.82% to $348388.0 in 2020, then skyrocketed by 86.71% to $650477.0 in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Operating Leases are $650477.0 (Q4 2021), $680526.0 (Q3 2021), and $709385.0 (Q2 2021).